BSE filing, NSE: MANKIND. Summary written from the filing by ALFA Finder's alert engine.
Mankind Pharma Ltd: key numbers
- Share price
- ₹2,492.80
- Market cap
- ₹1,02,964 Cr
- Revenue (annual)
- ₹14,278 Cr
- Net profit (annual)
- ₹1,913 Cr
- P/E (TTM)
- 45.9×Sector 45.9×
- Promoter holding
- 72.62%-0.01% QoQ
- FII holding
- 9.37%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Mankind Pharma Ltd
All →Mankind Pharma Credit Rating
CRISIL reaffirmed Mankind Pharma's AA+ rating on Rs.2,500 Crore of NCDs and withdrew ratings on Rs.2,500 Crore NCDs and Rs.1,500 Crore commercial paper. The rating action is dated October 29, 2026.
Mankind Pharma Earnings Call Transcript: Key Takeaways
Mankind Pharma delivered robust Q2 growth driven by chronic therapies and B-Spec specialty expansion. Strong operating leverage and margin expansion offset muted consumer health performance.
- Call
- Guides 20% growth
Mankind Pharma Investor Presentation: Key Takeaways
Q2 FY27 revenue ₹4,338 Cr (+17.3% YoY), EBITDA ₹1,175 Cr (27.1% margin), PAT ₹716 Cr (+37.7%). Domestic ex-CH +15.9%, exports +32.7%, CH +1.2%.
Mankind Pharma Results Update
Mankind Pharma reported Q2 FY27 revenue of ₹4,338 Cr, up 17% YoY, and PAT of ₹716 Cr, up 38%. EBITDA margin improved 210 bps to 27.1%.
Mankind Pharma Acquisition
Mankind Pharma's board approved amalgamation of two wholly owned subsidiaries into the parent and a step-down subsidiary merger into MCPPL. Schemes require NCLT and shareholder approvals.
Mankind Pharma Q2 FY27 Results: Net Profit ₹716.1 Cr, Up 37.7% YoY
Mankind Pharma Ltd reported revenue from operations of ₹4,338 Cr (+17.3% YoY) and net profit of ₹716.1 Cr (+37.7% YoY) for Q2 FY27.
- Key figure
- Net profit ₹716.1 Cr · +37.7% YoY
Other board meeting date announcements
All →Max Estates Board Meeting Date
Max Estates Limited has informed exchanges that its board will meet on 4 November 2026 to consider unaudited results for the quarter and half year ended 30 September 2026. The trading window stays closed until 6 November 2026.
GKP Printing & Packaging Board Meeting Date
G.K.P. Printing & Packaging announced a board meeting on 4 November 2026 to approve unaudited results for the quarter ended 30 September 2026. Trading window has been closed for insiders since 1 October 2026.
ADF Foods Board Meeting Date
ADF Foods will hold a board meeting on November 5, 2026 to consider unaudited results for the quarter and half year ended September 30, 2026. The meeting will also consider an interim dividend for FY2026-27.
MKP Mobility Board Meeting Date
MKP Mobility will hold a board meeting on November 6, 2026 to consider unaudited standalone and consolidated results for the quarter and half year ended September 30, 2026. Trading window remains closed until 48 hours after results.
Earkart Board Meeting Date
Earkart Limited gave prior intimation of a board meeting on 5 November 2026 to approve half-year results and incorporate an Australian subsidiary. The trading window stays closed until 7 November 2026.
Sabrimala Industries India Board Meeting Date
Sabrimala Industries India will hold a board meeting on 10 November 2026 to consider unaudited quarterly and half-year results. Trading window stays closed until 48 hours after results.